Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 5/20 | 0.39 |
| ▸ | TGM2 | P21980 | 5/20 | 0.39 |
| ▸ | TGM1 | P22735 | 5/20 | 0.39 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275145 | 1.00 | BTK (0.44) | BTKSCN9AEGFRERBB2ERBB3 | |
| SCHEMBL21275146 | 0.91 | SCN9A (0.42) | BTKSCN9AFPR2JAK3 | |
| SCHEMBL22712689 | 0.91 | SCN9A (0.42) | BTKSCN9AFPR2JAK3 | |
| SCHEMBL21275233 | 0.90 | BTK (0.42) | BTKEGFRJAK3 | |
| SCHEMBL22712699 | 0.86 | SCN9A (0.44) | BTKSCN9AFPR2 | |
| SCHEMBL21275166 | 0.86 | SCN9A (0.44) | BTKSCN9AFPR2 | |
| SCHEMBL30385106 | 0.83 | BTK (0.44) | BTKEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL21275177 | 0.82 | OPRM1 (0.34) | BTKSCN9AEGFRFPR2JAK3 | |
| SCHEMBL10256994 | 0.76 | JAK1 (0.42) | BTKEGFRFPR2JAK3 | |
| SCHEMBL1393372 | 0.74 | NAMPT (0.51) | BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250045728-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-02-06 | — | — | US | disclosed |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |
| CN-113939292-A | Inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2021066958-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200377478-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2020-12-03 | — | — | US | disclosed |
| CN-111741959-A | Inhibitors of BTK and mutants thereof | 新波制药有限公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | BTK 1/4885SCN9A 2896/4885EGFR 1870/4885 |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | BTK 1/4885SCN9A 1678/4885EGFR 927/4885 |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | BTK 1/4885SCN9A 1818/4885EGFR 970/4885 |
| US-20250045728-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | BTK 1/4885SCN9A 2195/4885EGFR 860/4885 |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | BTK 1/4885SCN9A 2195/4885EGFR 860/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | BTK 1/4885SCN9A 549/4885EGFR 905/4885 |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | BTK 1/4885SCN9A 2896/4885EGFR 1870/4885 |
| US-20200377478-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | BTK 1/4885SCN9A 2328/4885EGFR 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.